🔍

ALPA - Alpa Laboratorie

📊 NSE: ALPA 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 18:12

📢 Recent Corporate Announcements

Alpa Laboratories CS & Compliance Officer Srashti Chopra Resigns Effective March 25, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 25 Feb 2026, 06:46 PM

Alpa Laboratories Limited has announced the resignation of Ms. Srashti Chopra from her position as Company Secretary and Compliance Officer. The resignation was tendered on February 25, 2026, and will be effective from the close of business hours on March 25, 2026. The company stated the departure is due to personal reasons. As this is a statutory role, the company will need to appoint a successor to maintain compliance with SEBI listing regulations.

Ms. Srashti Chopra resigned as Company Secretary and Compliance Officer on February 25, 2026.
The resignation becomes effective from the close of business hours on March 25, 2026.
The departure is attributed to personal reasons with no other material concerns cited.
The company is now required to fill this Key Managerial Personnel (KMP) vacancy to ensure regulatory continuity.

💡 No immediate action is required as this is a routine administrative change. Investors should monitor for the appointment of a new Compliance Officer to ensure ongoing adherence to corporate governance standards.

Alpa Laboratories Q3 Net Profit Recovers to ₹1.87 Cr; Revenue Up 15.7% QoQ

🔵 WATCH ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 12:35 PM

Alpa Laboratories reported a strong sequential recovery in its financial performance for the quarter ended December 31, 2025. Standalone revenue from operations grew 15.7% quarter-on-quarter to ₹29.67 crore, while net profit surged to ₹1.87 crore from a marginal ₹0.10 crore in the previous quarter. However, year-on-year comparisons show a decline in total income and profit, primarily because the December 2024 quarter was bolstered by a high 'Other Income' of ₹8.80 crore. The nine-month EPS stands at ₹6.54, down from ₹10.31 in the previous year.

Standalone Revenue from operations increased to ₹29.67 crore in Q3 FY26 from ₹25.63 crore in Q2 FY26.
Net Profit (Standalone) recovered sharply to ₹1.87 crore compared to ₹0.10 crore in the preceding quarter.
Total income for the nine months ended Dec-25 reached ₹90.32 crore versus ₹93.40 crore in the prior year period.
Quarterly Earnings Per Share (EPS) improved to ₹0.89 from ₹0.05 sequentially.
Other Income dropped significantly to ₹0.26 crore in Q3 FY26 from ₹8.80 crore in Q3 FY25, impacting YoY growth metrics.

💡 Investors should focus on the sequential improvement in core operational revenue as a sign of recovery, while discounting the YoY decline caused by high non-operational income last year. Monitor the sustainability of these margins in the upcoming final quarter.

Alpa Laboratories Q3 Net Profit Drops 79% YoY to ₹1.87 Cr; Revenue Up 13.5%

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 12:24 PM

Alpa Laboratories reported a significant year-on-year decline in net profit for Q3 FY26, with standalone PAT falling 78.9% to ₹1.87 crore. This sharp drop is primarily attributed to a high base effect, as 'Other Income' plummeted from ₹8.80 crore in Q3 FY25 to just ₹0.26 crore this quarter. However, core operations showed resilience with revenue from operations growing 13.5% YoY to ₹29.67 crore. Sequentially, the company demonstrated a strong recovery from a very weak Q2 FY26 where profit was nearly flat at ₹0.10 crore.

Standalone Revenue from operations increased 13.5% YoY to ₹2,967.12 lacs.
Net Profit (PAT) for the quarter stood at ₹187.48 lacs, down from ₹889.30 lacs in the previous year.
Other Income saw a massive reduction to ₹26.05 lacs from ₹880.17 lacs in the same quarter last year.
Nine-month (9M FY26) standalone PAT declined to ₹1,375.20 lacs compared to ₹2,166.42 lacs in 9M FY25.
Earnings Per Share (EPS) for the quarter dropped to ₹0.89 from ₹4.24 YoY.

💡 The headline profit decline is misleading due to the absence of high 'Other Income' seen last year; investors should focus on the 13.5% growth in core operational revenue. While the sequential recovery is a positive sign, the stock remains a watch until margins stabilize consistently.

Alpa Laboratories Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Dec 2025, 04:46 PM

Alpa Laboratories Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations for the upcoming financial results. The window will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ending December 31, 2025. This is a standard regulatory procedure followed by listed companies to prevent insider trading during the finalization of quarterly accounts.

Trading window closure effective from January 1, 2026
Closure pertains to the unaudited financial results for the quarter ending December 31, 2025
Window to reopen 48 hours after the official announcement of financial results
Complies with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018

💡 No action is required as this is a routine regulatory filing. Investors should wait for the upcoming quarterly results to assess the company's financial performance.

View All ALPA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment of Drugs & Chemicals, which achieved a standalone total income of INR 13,575.71 Lacs in FY 2024-25, representing a growth of 9.82% compared to INR 12,361.28 Lacs in the previous year.

Geographic Revenue Split

Not disclosed in available documents, although the company highlights a strategic focus on expanding export revenues and penetrating new international markets.

Profitability Margins

Profit After Tax (PAT) margin stood at 14.6% for FY 2024-25, with PAT increasing 17.62% YoY to INR 1,982.90 Lacs. Profit Before Tax (PBT) grew by 24.99% to INR 2,584.12 Lacs.

EBITDA Margin

EBITDA margin improved to 20.85% in FY 2024-25 from 18.62% in FY 2023-24, with absolute EBITDA growing 22.99% to INR 2,830.99 Lacs.

Capital Expenditure

Property, plant, and equipment (standalone) was valued at INR 2,105.38 Lacs as of September 30, 2025. Net cash outflow for the purchase of property, plant, and equipment was INR 166.82 Lacs for the half-year ended September 2025.

Credit Rating & Borrowing

The company's bank facilities are rated 'CRISIL B/Stable/CRISIL A4 Issuer Not Cooperating'. Interest charges decreased by 31.60% YoY to INR 26.63 Lacs in FY 2024-25, indicating reduced borrowing costs or debt levels.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) and other key raw materials represent approximately 52% of total income, with costs amounting to INR 7,071.93 Lacs in FY 2024-25.

Import Sources

Not disclosed in available documents; however, the company notes a significant dependence on imported APIs.

Capacity Expansion

Not disclosed in available documents, but the permanent workforce increased by 10.48% to 453 employees in FY 2024-25 to support expanding operations.

Raw Material Costs

Cost of materials consumed was INR 7,071.93 Lacs in FY 2024-25. For the half-year ended September 2025, standalone material costs were INR 2,849.50 Lacs, representing 47.1% of total income for that period.

📈 Strategic Growth

Expected Growth Rate

9.82%

Growth Strategy

Growth will be driven by expanding the geographic footprint in overseas markets to enhance export revenues, investing in R&D for new product launches, and upgrading manufacturing facilities to meet global compliance standards like USFDA and EMA.

Products & Services

The company manufactures a wide range of pharmaceutical products, specifically generic formulations and drugs & chemicals.

Brand Portfolio

Alpa Laboratories.

Market Expansion

Strategic entry into new international markets is identified as a key driver for future topline growth.

🌍 External Factors

Industry Trends

The industry is seeing heightened scrutiny from USFDA, EMA, and WHO. There is a shift toward biotechnology and digital healthcare, requiring companies to adopt new technologies to avoid obsolescence.

Competitive Landscape

Intense competition from domestic players, multinational corporations, and generic manufacturers in both domestic and international markets.

Competitive Moat

Moat is built on WHO-GMP and ISO 9001:2000 certifications and a diversified product portfolio. Sustainability depends on maintaining high compliance standards to differentiate from domestic competitors.

Macro Economic Sensitivity

Highly sensitive to inflation and interest rate fluctuations, which impact operational costs and the 31.60% reduction in interest charges seen in FY25.

Geopolitical Risks

Trade restrictions and changing geopolitical dynamics are cited as risks that may affect exports and overall profitability.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the National Pharmaceutical Pricing Authority (NPPA) for pricing and global bodies like USFDA, EMA, and WHO for manufacturing standards.

Environmental Compliance

The company is subject to environmental regulations and climate-related sustainability mandates, though specific compliance costs are not disclosed.

Taxation Policy Impact

The effective tax rate for FY 2024-25 was approximately 23.8%, with total tax and deferred tax expenses rising 58.13% to INR 616.18 Lacs.

Legal Contingencies

The company has pending litigations disclosed in Note 35 of its financial statements, though management and auditors state these are not expected to have a material impact on the financial position.